Ivosidenib
FDA-approved product (tablet, oral), marketed as Tibsovo.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Acute myeloid leukemia
- Cholangiocarcinoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Isocitrate dehydrogenase (idh) inhibitors
- FDA pharmacologic class
- Isocitrate Dehydrogenase 1 Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA58.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae34.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ivosidenib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Trimetrexate GlucuronateExisting use: Other agents against amoebiasis and other protozoal diseases88.6% AI-predicted activityagainst E. coliLab records exist17 registered studies
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more87.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more86.8% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more82.2% AI-predicted activityagainst E. coli44 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives81.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Leucovorin CalciumExisting use: Osteosarcoma67.6% AI-predicted activityagainst E. coli50+ registered studies
- LevoleucovorinExisting use: Anemia, Colorectal adenocarcinoma, Colorectal cancer and 3 more67.6% AI-predicted activityagainst E. coli50+ registered studies
- PyrimethamineExisting use: Malaria, Toxoplasmosis64.6% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells63.5% AI-predicted activityagainst E. coli10 registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria62.6% AI-predicted activityagainst E. coli23 registered studies
- Rimegepant SulfateExisting use: Migraine disorder61.6% AI-predicted activityagainst E. coli50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer61.6% AI-predicted activityagainst E. coli13 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.
NCT07463768 · start 2026-09
Registered record
- Registry ID
- NCT07463768
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Ivosidenib + oral azacitidine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2026-09
- Completion
- 2030-09
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Myeloid LeukemiaInterventionIvosidenib + oral azacitidinePhasePhase 2Registry statusNot yet recruitingIvosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients
NCT07809893 · start 2026-08-10
Registered record
- Registry ID
- NCT07809893
- Conditions
- Colorectal Cancer
- Interventions
- Ivonescimab +mFOLFOXIRI +celecoxib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2026-08-10
- Completion
- 2028-06-30
- Enrolment
- 45
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal CancerInterventionIvonescimab +mFOLFOXIRI +celecoxibPhasePhase 2Registry statusRecruitingOral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients
NCT07507760 · start 2026-06-12
Registered record
- Registry ID
- NCT07507760
- Conditions
- Acute Myeloid Leukemia With Gene Mutations
- Interventions
- Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET; Ivosidenib Oral Tablet; Hydroxyurea; Cytarabine; Allogeneic stem cell transplantation
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2026-06-12
- Completion
- 2029-04
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Myeloid Leukemia With Gene MutationsInterventionDecitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET; Ivosidenib Oral Tablet; Hydroxyurea; Cytarabine +1 morePhasePhase 2Registry statusRecruitingIvosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS
NCT07607418 · start 2026-05-22
Registered record
- Registry ID
- NCT07607418
- Conditions
- AML (Acute Myeloid Leukemia); MDS (Myelodysplastic Syndrome)
- Interventions
- Ivosidenib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2026-05-22
- Completion
- 2027-12-30
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAML (Acute Myeloid Leukemia); MDS (Myelodysplastic Syndrome)InterventionIvosidenibPhasePhase 2Registry statusRecruitingA Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
NCT07392242 · start 2026-01-27
Registered record
- Registry ID
- NCT07392242
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Ivosidenib; Azacitidine; Venetoclax
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2026-01-27
- Completion
- 2028-01
- Enrolment
- 45
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Myeloid LeukemiaInterventionIvosidenib; Azacitidine; VenetoclaxPhasePhase 2Registry statusRecruitingIvosidenib as Post-HSCT Maintenance for AML
NCT06707493 · start 2026-01-16
Registered record
- Registry ID
- NCT06707493
- Conditions
- IDH1 Mutation; Acute Myeloid Leukemia (AML); Hematopoietic Stem Cell Transplant (HSCT)
- Interventions
- Ivosidenib; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2026-01-16
- Completion
- 2030-01-01
- Enrolment
- 75
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIDH1 Mutation; Acute Myeloid Leukemia (AML); Hematopoietic Stem Cell Transplant (HSCT)InterventionIvosidenib; PlaceboPhasePhase 2Registry statusRecruitingA Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
NCT07006688 · start 2026-01-14
Registered record
- Registry ID
- NCT07006688
- Conditions
- IDH1-Mutated Malignancies
- Interventions
- Ivosidenib Oral Tablet
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Recruiting
- Start
- 2026-01-14
- Completion
- 2028-08-31
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIDH1-Mutated MalignanciesInterventionIvosidenib Oral TabletPhasePhase 1Registry statusRecruitingRepeatability of Magnetic Resonance Imaging in Patients With IDH1 Mutant Glioma on Ivosidenib
NCT06648473 · start 2026-01-01
Registered record
- Registry ID
- NCT06648473
- Conditions
- Low Grade Glioma of Brain
- Interventions
- MRI Scan
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Withdrawn
- Start
- 2026-01-01
- Completion
- 2027-12-01
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLow Grade Glioma of BrainInterventionMRI ScanPhaseNot applicableRegistry statusWithdrawnPhase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
NCT07260175 · start 2025-11-18
Registered record
- Registry ID
- NCT07260175
- Conditions
- Cholangiocarcinoma; IDH Mutation
- Interventions
- Ivosidenib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2025-11-18
- Completion
- 2031-12
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCholangiocarcinoma; IDH MutationInterventionIvosidenibPhasePhase 2Registry statusRecruitingVenetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
NCT06611839 · start 2025-10-17
Registered record
- Registry ID
- NCT06611839
- Conditions
- AML; IDH1 Mutation; Treatment
- Interventions
- Ivosidenib, Venetoclax, Azacitidine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Recruiting
- Start
- 2025-10-17
- Completion
- 2028-10-01
- Enrolment
- 23
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAML; IDH1 Mutation; TreatmentInterventionIvosidenib, Venetoclax, AzacitidinePhasePhase 1 / Phase 2Registry statusRecruitingProspective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation
NCT06717958 · start 2025-06-17
Registered record
- Registry ID
- NCT06717958
- Conditions
- AML; MDS
- Interventions
- Ivosidenib 250 MG (milligram)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2025-06-17
- Completion
- 2030-02-01
- Enrolment
- 76
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAML; MDSInterventionIvosidenib 250 MG (milligram)PhasePhase 2Registry statusRecruitingIMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
NCT06713837 · start 2025-02-27
Registered record
- Registry ID
- NCT06713837
- Conditions
- Acute Myeloid Leukemia; Relapse/Recurrence
- Interventions
- High intensity therapies; Low intensity therapies
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2025-02-27
- Completion
- 2028-01
- Enrolment
- 339
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Myeloid Leukemia; Relapse/RecurrenceInterventionHigh intensity therapies; Low intensity therapiesPhasePhase 3Registry statusRecruitingIvosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
NCT06501625 · start 2024-12-16
Registered record
- Registry ID
- NCT06501625
- Conditions
- Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
- Interventions
- Ivosidenib; Durvalumab (for the first 8, 21-day, cycles); Gemcitabine (for the first 8, 21-day, cycles); Cisplatin (for the first 8, 21-day, cycles); Durvalumab (starting from cycle 9); Ivosidenib Recommended Combination Dose (RCD)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Recruiting
- Start
- 2024-12-16
- Completion
- 2027-09-13
- Enrolment
- 52
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLocally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 MutationInterventionIvosidenib; Durvalumab (for the first 8, 21-day, cycles); Gemcitabine (for the first 8, 21-day, cycles); Cisplatin (for the first 8, 21-day, cycles) +2 morePhasePhase 1 / Phase 2Registry statusRecruitingLvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer
NCT06593548 · start 2024-11-01
Registered record
- Registry ID
- NCT06593548
- Conditions
- CRC; MSS; Metastatic Cancer
- Interventions
- Ivosidenib (AK112)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2024-11-01
- Completion
- 2026-11-01
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCRC; MSS; Metastatic CancerInterventionIvosidenib (AK112)PhasePhase 2Registry statusNot yet recruitingIvosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
NCT06291987 · start 2024-09-19
Registered record
- Registry ID
- NCT06291987
- Conditions
- Myeloproliferative Neoplasms
- Interventions
- Ivosidenib; Ruxolitinib
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Recruiting
- Start
- 2024-09-19
- Completion
- 2029-05
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMyeloproliferative NeoplasmsInterventionIvosidenib; RuxolitinibPhasePhase 1Registry statusRecruiting